Relationship of PPARgamma2 Polymorphism with Obesity and Metabolic Syndrome in Postmenopausal Polish Women

 

 Buy Article Permissions and Reprints

Abstract

Objective: The contribution of genetic factors to the development of menopausal obesity has been widely recognized. Peroxisome proliferator-activated receptor gamma (PPARγ) is involved in adipocyte differentiation and has been suggested to influence insulin sensitivity. The aim of this study was to evaluate the frequency of Pro12Ala PPARγ polymorphism and its association with body mass index (BMI) and metabolic syndrome parameters in postmenopausal Polish women.

Material and Methods: The study was performed in 318 postmenopausal women aged 50–60 years randomly selected from the Wrocław city population with BMI ranging from 17.5 to 46.38 kg/m² (mean BMI 27.5±4.78 kg/m²). Anthropometric parameters, body composition (total body fat, android and gynoid deposits, using DXA) and biochemical parameters (lipid profile, glucose, and insulin levels) were measured and QUICKI was calculated. PPARγ genotyping was performed by PCR and minisequencing using an ABI 310 sequencer (Applied Biosystems).

Results: The Pro12Ala genotype was found in 26% of the women, but Ala12Ala only in 4%. Metabolic syndrome was recognized in 16% of all the women, 14% of the women with Pro12Pro genotype, 21% of the Pro12Ala carriers, and 14% of the women with the Ala12Ala variant. Obese women with at least one Ala allele (X/Ala genotype) showed higher serum levels of total cholesterol (265.7±44.5 mg/dl vs. 233.2±38.1 mg/dl, p<0.001), LDL cholesterol (171.8±37.8 mg/dl vs. 143.7±34.8 mg/dl; p<0.001), and triglycerides (149.4±55.2 mg/dl vs. 126.8±54.2 mg/dl, p<0.05) compared with the women with the Pro12Pro genotype.

Conclusions:The Pro12Ala PPARγ polymorphism does not seem to be associated with BMI or metabolic syndrome parameters in postmenopausal Polish women, although the X/Ala genotype seems to predispose to a less favorable lipid profile in this population.

References

• 1 Altshuler D, Hirschhorn JN, Klannemark M. et al . The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.  Nat Genet. 2000;  26 76-80
  CrossrefPubMedGoogle Scholar
• 2 Beamer BA, Yen CJ, Andersen RE. et al . Association of the Pro12Ala variant in the peroxisome proliferator–activated receptor-γ2 gene with obesity in two Caucasian populations.  Diabetes. 1998;  47 1806-1808
  PubMedGoogle Scholar
• 3 Deeb SS, Fajas L, Nemoto M. et al . A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.  Nat Genet. 1998;  20 284-287
  CrossrefPubMedGoogle Scholar
• 4 Ek J, Urhammer SA, Sørensen TI. et al . Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men.  Diabetologia. 1999;  42 892-895
  CrossrefPubMedGoogle Scholar
• 5 Franks PW, Luan J, Browne PO. et al . Does peroxisome proliferator-activated receptor gamma genotype (Pro12Ala) modify the association of physical activity and dietary fat with fasting insulin level?.  Metabolism. 2004;  53 11-16
  CrossrefPubMedGoogle Scholar
• 6 Frederiksen L, Brødbaek K, Fenger M. et al . Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome.  J Clin Endocrinol Metab.. 2002;  87 3989-3992
  CrossrefPubMedGoogle Scholar
• 7 Giusti V, Suter M, Verdumo C. et al . Molecular determinants of human adipose tissue: differences between visceral and subcutaneous compartments in obese women.  J Clin Endocricol Metab. 2004;  89 1379-1384
  CrossrefPubMedGoogle Scholar
• 8 González Sánchez JL, Serrano Ríos M, Fernández Perez C. et al . Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population.  Eur J Endocrinol.. 2002;  147 495-501
  CrossrefPubMedGoogle Scholar
• 9 Greenfield JR, Samaras K, Chisholm DJ. Insulin resistance, intra-abdominal fat, cardiovascular risk factors, and androgens in healthy young women with type I diabetes mellitus.  J Clin Endocrinol Metab.. 2002;  87 1036-1040
  CrossrefPubMedGoogle Scholar
• 10 Hara K, Okada T, Tobe K. et al . The Pro12Ala polymorphism in PPARγ2 may confer resistance to type 2 diabetes.  Biochem Biophys Res Commun. 2000;  271 212-216
  CrossrefPubMedGoogle Scholar
• 11 Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology.  Biochim Biophys Acta. 2007;  1771 999-1013
  PubMedGoogle Scholar
• 12 Katz A, Nambi SS, Mather K. et al . Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.  J Clin Endocrinol Metab. 2000;  85 2402-2410
  CrossrefPubMedGoogle Scholar
• 13 Knoblauch H, Busjahn A, Müller-Myhsok B. et al . Peroxisome proliferator-activated receptor gamma gene locus is related to body mass index and lipid values in healthy nonobese subjects.  Arterioscler Thromb Vasc Biol. 1999;  19 2940-2944
  PubMedGoogle Scholar
• 14 Kolehmainen M, Uusitupa MI, Alhava E. et al . Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects.  J Clin Endocrinol Metab. 2003;  88 1717-1722
  CrossrefPubMedGoogle Scholar
• 15 Lai K, Harnish DC, Evans MJ. Estrogen receptor alpha regulates expression of the orphan receptor small heterodimer partner.  J Biol Chem. 2003;  278 36418-36429
  CrossrefPubMedGoogle Scholar
• 16 Luan J, Browne PO, Harding AH. et al . Evidence for gene-nutrient interaction at the PPARgamma locus.  Diabetes. 2001;  50 686-689
  PubMedGoogle Scholar
• 17 Mancini FP, Vaccaro O, Sabatino L. et al . Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes.  Diabetes. 1998;  48 1466-1468
  PubMedGoogle Scholar
• 18 Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis.  J Med Genet. 2003;  40 773-780
  CrossrefPubMedGoogle Scholar
• 19 Mattevi VS, Zembrzuski VM, Hutz MH. Effects of a PPARγ gene variant on obesity characteristics in Brazil.  Braz J Med Biol Res. 2007;  40 927-932
  PubMedGoogle Scholar
• 20 Meirhaeghe A, Amouyel P. Impact of genetic variation of PPAγ gamma in humans.  Mol Genet Metab. 2004;  83 93-102
  CrossrefPubMedGoogle Scholar
• 21 Meirhaeghe A, Fajas L, Helbecque N. et al . Impact of the peroxisome proliferator-activated receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus.  Int J Obesity. 2000;  24 195-199
  PubMedGoogle Scholar
• 22 Milewicz A, Tworowska U, Demissie M. Menopausal obesity–myth or fact?.  Climacteric. 2001;  4 273-283
  CrossrefPubMedGoogle Scholar
• 23 Mori H, Ikegami H, Kawaguchi Y. et al . The Pro12 – >Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes.  Diabetes. 2001;  50 891-894
  PubMedGoogle Scholar
• 24 Ringel J, Engeli S, Distler A. et al . Pro12Ala missense mutation of the peroxisome proliferator-activated receptor γ and diabetes mellitus.  Biochem Biophys Res Commun. 1999;  254 450-453
  CrossrefPubMedGoogle Scholar
• 25 Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease.  J Clin Invest. 2006;  116 581-589
  CrossrefPubMedGoogle Scholar
• 26 Soriguer F, Morcillo S, Cardona F. et al . Pro12Ala polymorphism of the PPARγ2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid.  J Nutr. 2006;  136 2325-2330
  PubMedGoogle Scholar
• 27 Tonjes A, Scholz M, Loeffler M. et al . Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals.  Diabetes Care. 2006;  29 2489-2497
  CrossrefPubMedGoogle Scholar
• 28 Valve R, Sivenius K, Miettinen R. et al . Two polymorphisms in the peroxisome proliferator-activated receptor γ gene are associated with severe overweight among obese women.  J Clin Endocrinol Metab. 1999;  84 3708-3712
  CrossrefPubMedGoogle Scholar
• 29 Vidal-Puig A, Considine R, Jimenez-Linan M. et al . Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids.  J Clin Invest. 1997;  99 2416-2422
  CrossrefPubMedGoogle Scholar
• 30 Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome.  End Rev. 2000;  21 637-738
  PubMedGoogle Scholar
• 31 Yen CJ, Beamer BA, Negri C. et al . Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation.  Biochem Biophys Res Commun. 1997;  241 270-274
  CrossrefPubMedGoogle Scholar
• 32 Zimmet P, Alberti G, Shaw J. A new IDF worldwide definition of the metabolic syndrome: the rationale and the results.  Diabetes Voice. 2005;  50 31-33
  PubMedGoogle Scholar

Correspondence

Prof. A. MilewiczMD, PhD 

Endocrinology, Diabetology and Isotope Treatment

Wroclaw Medical University

Poland

ul. Pasteura 4

50–367 Wroclaw

Poland

Email: milewicz@endo.am.wroc.pl